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Abstract
Horses are more prone to complications in the wound healing process than other species, and problems such as chronic inflam-
mation, delayed epithelialization, poor wound contraction, and exuberant granulation tissue are commonly seen, particularly in
wounds on the distal limbs. In comparison, wounds of the oral mucosa heal rapidly in a scarless fashion with a high degree of wound
contraction. The effect of platelet-derived growth factor BB (PDGF), insulin-like growth factor (IGF)-1, and transforming growth
factor 1 (TGF1) on the contraction of a fibroblast-populated collagen matrix (FPCM) as a model of equine wound contraction
was investigated using equine oral fibroblasts. The fibroblasts were embedded into floating FPCM and treated with PDGF, IGF-1,
and TGF1. The surface areas of the FPCM were determined daily for 5 d. Platelet-derived growth factor significantly stimulated
the contraction of the FPCM at an optimal concentration of 10 ng/mL (P = 0.025). Insulin-like growth factor-1 and TGF1 did not
significantly affect the contraction of the FPCM relative to the control. To elucidate the mechanisms by which PDGF stimulated
contraction of FPCM, the Rho-kinase and p38 cell signaling pathways were blocked, resulting in a significant inhibition (P < 0.001)
of PDGF-stimulated contraction. Platelet-derived growth factor BB is a potent stimulator of fibroblast migration, and hence the
FPCM contraction generated here is probably a result of its effects on cell migration. The results of the present experiment suggest
that this effect is stimulated via both the Rho-kinase and p38 signaling pathways in equine oral fibroblasts.
© 2009 Elsevier Inc. All rights reserved.
Keywords: equine fibroblasts; wound contraction; platelet-derived growth factor; insulin-like growth factor 1; transforming growth factor 1;
Rho-kinase
1. Introduction
Wound healing in horses is more problematic than
in other species because of the common problems of
chronic inflammation, exuberant granulation tissue, and
poor wound contraction [1]. Distal limb wounds are
particularly prone to slow healing with unsightly scar
∗ Corresponding author. Tel.: +44 1970 621682;
fax: +44 1970 611264.
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formation, but in comparison, oral wounds heal in a
scarless fashion [2,3]. Wound contraction is an impor-
tant process in determining the strength and size of the
final scar tissue, as it pulls the uninjured tissue from
the peri-wound area to cover the wound [4]. Therefore,
manipulation of wound contraction offers an attractive
method for increasing the speed and quality of healing.
There are two main processes that work together
to bring about wound contraction: contraction result-
ing from generation of tractional force by migrating
fibroblasts or contraction as a result of myofibroblast
contraction [5]. Wound contraction is initiated by fibrob-
0739-7240/$ – see front matter © 2009 Elsevier Inc. All rights reserved.
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lasts producing tractional force as they migrate into the
provisional matrix of the wound around day 5 post-
injury under the influence of a variety of growth factors,
including platelet-derived growth factor BB (PDGF) and
insulin-like growth factor (IGF) [6]. This migration is
controlled by various cell signaling pathways including
Rho-kinase and p38 [7–9]. The initiation of contrac-
tion via the tractional force generated by fibroblasts
migrating through the provisional extracellular matrix
(ECM) increases tension within the wound to the thresh-
old required to trigger fibroblasts to differentiate into
myofibroblasts [10]. Although myofibroblast differen-
tiation depends on a number of factors, including the
presence of transforming growth factor 1 (TGF1) and
the ED-A splice variant of fibronectin, neither of these
alone is sufficient to trigger differentiation in the absence
of matrix tension of approximately 20,000 Pa [11–13].
Thus the increase in tension as a result of tractional force
is an essential aspect of wound contraction, and there-
fore the generation of tractional force as a result of the
application of different growth factors was the primary
focus of this research.
Although a large number of hormones and growth fac-
tors are known to affect wound healing, there is currently
no published research examining the effect of PDGF,
IGF-1, or TGF1 on in vitro models of wound contrac-
tion in horses, nor is there any research examining the
ability of equine oral mucosal cells to contract fibroblast-
populated collagen matrices (FPCM). Therefore, the
objective of the first experiment was to determine the
effect of these growth factors on the contraction of float-
ing FPCM containing equine cells harvested from the
mucosal surface of the buccal cavity, as understanding
the mechanisms that lead to scarless healing may provide
insight into methods to decrease scarring in other sites
of the body, particularly the limbs. Floating FPCM con-
tract as a result of tractional force generated by migrating
fibroblasts rearranging the collagen fibers into a more
orderly pattern, and the fibroblasts do not differentiate
into myofibroblasts [14]. Whilst in vivo, fibroblasts are
stimulated to migrate in a directional manner under the
influence of growth factors and ECM proteins [6], and
the migration within the FPCM is in a nondirectional
manner, the mechanisms by which the tractional force
is generated and the collagen rearranged are the same,
thus making FPCM a suitable model to investigate the
role of tractional force in the initiation of wound con-
traction. Based on the results of the first experiment, the
objective of the second experiment was to inhibit the
intracellular signaling enzymes Rho-kinase and p38 to
determine their importance in PDGF-stimulated contrac-
tion of FPCM.
2. Materials and methods
All chemicals were purchased from Sigma Aldrich
(Poole, UK).
2.1. Initial isolation and establishment of clonal
equine oral mucosal fibroblasts
Fibroblast cultures were established from the mucosal
surface of the buccal cavity of 4 horses immediately fol-
lowing euthanasia for unrelated reasons. There were no
obvious signs of wounds, scars, or dermatological condi-
tions on the tissue harvested. Samples were transported
to the laboratory on ice in tubes containing serum-free
Dulbecco’s modified Eagle’s medium (DMEM) with 5%
penicillin/streptomycin (P/S) and 5% amphotericin B.
Within 3 h, the skin was washed in phosphate-buffered
saline (PBS) containing 5% P/S and 5% amphotericin
B. Subcutaneous tissue was removed and the samples
minced into approximately 1-2 mm2 pieces. Samples
were incubated for 45 min in 0.25% trypsin at 37 ◦C
in a shaking incubator. The cell suspension was filtered
through a steel mesh before centrifugation at 1,000 rpm
for 5 min at 4 ◦C. The pellet was resuspended in DMEM
and centrifuged 2 more times. Cells were plated onto tis-
sue culture flasks and grown in DMEM with 10% fetal
bovine serum (FBS) and 5% P/S and 5% amphotericin B
at 37 ◦C in 5% CO2. Antibiotics were removed from the
medium after the first week. Medium was changed at 48-
72-h intervals, and cells were passaged at confluency by
treatment with 0.05% trypsin/EDTA for 5 min. Unless
otherwise stated, throughout the study, cells were plated
in flasks at a concentration of 1.0 × 104 cells/cm2, and
cell numbers were determined using a hemocytometer.
This primary culture was then cloned to increase
genetic stability through a process of limiting dilution.
This process involved detaching adherent cells with
0.05% trypsin/EDTA for 5 min at the second passage.
Trypsin was subsequently inhibited by the addition of
DMEM containing 10% FBS, and the cells were gen-
tly, but thoroughly, pipetted to ensure dissociation of
clumps of cells. Cells were then diluted to 10 cells/mL in
DMEM plus 10% FBS via multiple dilutions. A volume
of 200L was then added to each well of a 96-well plate.
Wells containing a single colony grown from a single cell
were first multiplied up into a 24-well plate, then a 6-well
plate, before growing in a 25 cm2 flask. When conflu-
ent, excess cells were cryopreserved in 10% dimethyl
sulphoxide (DMSO)/dextran solution (containing 10 g
dextran/50 mL DMSO) and 90% FBS. One clone (based
on proliferative activity and stability of karyotype num-
ber) was selected for future experiments.
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2.2. Experiment 1: Effect of growth factors on
FPCM contraction
Floating FPCM were prepared by mixing 0.762 mL
of 2 × concentrated DMEM, with 4.02 mL of collagen
dissolved in 20 mmol acetic acid (2 mg collagen/mL)
neutralized with 0.2 mL NaOH, to which 3.96 × 105 oral
fibroblasts were added. The final concentration of fibrob-
lasts was 8.3 × 104 cells/mL and 1.6 mg/mL collagen. A
volume of 0.4 mL of this collagen and cell suspension
was then pipetted into 12 wells of a 48-well plate. Matri-
ces were allowed to set in an incubator for 30 min at 37 ◦C
and 5% CO2. Once set, each matrix was carefully trans-
ferred to a well of a 24-well plate. A volume of 1 mL
DMEM containing 2% FBS and the appropriate treat-
ment was added to each well. The treatments were: no
addition (control); PDGF-BB (10, 50, or 100 ng/mL);
IGF-1 (20, 100, or 400 ng/mL); or TGF1 (2, 10, or
20 ng/mL). All growth factors were human in origin.
Growth factor concentrations were chosen based on the
concentrations most commonly used in previously pub-
lished literature [15–17]. To make the imaging of the
gels easier, phenol red-free DMEM was used through-
out. The matrices were scanned daily for 5 d using a
BioRad GS-800 calibrated densitometer, and the surface
area was determined using Quantity One software (Build
4.5.0, Bio-Rad Laboratories, Watford, UK, 2003).
2.3. Experiment 2: Effect of inhibiting Rho-kinase
and p38 on PDGF-stimulated FPCM contraction
The effect of inhibiting Rho-kinase and p38 signaling
enzymes on the contraction of PDGF-stimulated float-
ing FPCM was investigated by inclusion of signaling
inhibitors in the FPCM medium. Two different inhibitors
were used for each pathway to account for different lev-
els of inhibition specificity [18]. The preparation of the
FPCM was slightly modified from that of Experiment 1
to create larger FPCM. For each plate, 9.0 × 105 fibrob-
lasts, 1.715 mL of 2 × concentrated DMEM, 9.06 mL of
collagen, and 0.45 mL NaOH were mixed. A volume of
0.6 mL of the collagen/cell solution was pipetted into 18
wells of a 24-well plate and when set, the solution was
transferred to a 12-well plate. The final concentrations
of collagen and cells in the FPCM were the same as for
Experiment 1.
For each signaling pathway investigated, 3 controls
were set up: 2% FBS only, and 2% FBS plus one of the
two inhibitors for the pathway being investigated. For
Rho-kinase, the inhibitors used were Y-27632 (10M)
and hydroxyfasudil (20M), and for p38, SB203580
(10M) and SB202190 (10M) in 0.1% DMSO were
Fig. 1. Effect of platelet-derived growth factor BB on the relative sur-
face area of fibroblast-populated collagen matrix. Least significant
difference: 7.313. Platelet-derived growth factor BB (10 ng/mL) caused
a significantly greater (P = 0.025) contraction compared to the control
(0 ng/mL); there was no significant difference between the 10, 50, and
100 ng/mL treatments.
used. Additionally, a positive control of 10 ng/mL PDGF
with 2% FBS was used in each case. Finally, for each
pathway, FPCM were set up containing 10 ng/mL PDGF
with 2% FBS plus one of the two inhibitors. All inhibitors
were well characterized for their specificity of inhibition
[18].
2.4. Calculations and statistical analysis
The surface areas of the matrices were expressed as
a percentage of the original area on day 0, and statisti-
cal analyses were carried out using these percentages.
All experiments were replicated 3 times from a separate
batch of cells, with each replicate containing each treat-
ment in triplicate. Results for each individual growth
factor or enzyme were analyzed using split-plot analysis
of variance; the main effect was treatment and the split
plot was day of incubation. Differences of P ≤ 0.05 were
taken as significant. Significant differences were deter-
mined using least significant difference (LSD), with a
percentage difference between two results greater than
the LSD taken as significant.
3. Results
3.1. Experiment 1: Effect of growth factors on
FPCM contraction
Platelet-derived growth factor stimulated the con-
traction of the FPCM relative to the control at all
concentrations investigated (P = 0.025; Fig. 1). How-
ever, there was no difference between any of the PDGF
treatments, indicating that 10 ng/mL was at or above
the concentration that causes maximal contraction of the
FPCM. Insulin-like growth factor-1 did not significantly
Author's personal copy
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Fig. 2. Effect of insulin-like growth factor-1 on the relative surface area
of fibroblast-populated collagen matrix. Least significant difference:
5.065. Split-plot analysis of variance revealed that there was no overall
significant difference between the treatments in this experiment, but
there was a significant interaction (P = 0.028); the control (0 ng/mL)
treatment reached a plateau by day 2, but the insulin-like growth factor-
1 treatments containing 20 or 100 ng/mL were still contracting on day
5.
affect the average contraction of the FPCM relative to the
control over the 5-d period of the experiment (Fig. 2).
However, there was a significant interaction (P = 0.028)
such that the control treatment reached a plateau by day
2, whereas FPCM treated with either 20 or 100 ng/mL
IGF continued to contract and were still contracting on
day 5. Transforming growth factor 1 did not affect
FPCM contraction relative to the control at any concen-
tration investigated (Fig. 3).
3.2. Experiment 2: Effect of inhibiting Rho-kinase
and p38 on PDGF-stimulated FPCM contraction
Addition of either of the Rho-kinase inhibitors
blocked PDGF-stimulated contraction (P < 0.001) with-
out affecting basal levels of contraction (Fig. 4).
Similarly, addition of either of the p38 inhibitors had a
Fig. 3. Effect of transforming growth factor 1 on the relative surface
area of fibroblast-populated collagen matrix. Least significant differ-
ence: 5.980. There was no significant effect of transforming growth
factor 1 at any concentration tested on the contraction of the gels.
Fig. 4. Effect of the Rho-kinase inhibitors Y-27632 and hydrox-
yfasudil on platelet-derived growth factor BB (PDGF)-stimulated
contraction of fibroblast-populated collagen matrix. Least significant
difference: 4.591. Treatment with 10 ng/mL PDGF stimulated a sig-
nificant increase (P < 0.001) in contraction compared to all other
treatments, and addition of either of the Rho-kinase inhibitors reduced
PDGF-stimulated contraction back to control levels (P < 0.001).
Fig. 5. Effect of the p38 inhibitors SB203580 and SB202190 on
platelet-derived growth factor BB (PDGF)-stimulated contraction of
fibroblast-populated collagen matrix. Least significant difference:
4.348. Treatment with 10 ng/mL PDGF stimulated a significant
increase (P < 0.001) in contraction compared to all other treatments,
and addition of either of the p38 inhibitors reduced PDGF-stimulated
contraction back to control levels (P < 0.001).
similar effect in blocking PDGF-stimulated contraction
(P < 0.001) without affecting basal levels of contraction
(Fig. 5). Inclusion of an equivalent amount of DMSO
only (in which the p38 inhibitors were dissolved) did
not affect contraction (data not shown). These results
suggest that both Rho-kinase and p38 are important in
the generation of tractional force in FPCM stimulated
with PDGF.
4. Discussion
Of the 3 growth factors tested in Experiment 1, PDGF
was the only one to significantly stimulate contraction
of FPCM, with a maximal effect at 10 ng/mL. These
results are in agreement with data published using this
Author's personal copy
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methodology in other species [16,19,20]. Floating matri-
ces contract predominantly because of tractional forces
resulting from fibroblast migration [14], and PDGF is a
strong chemotactic agent, present in high concentrations
early in the healing process [6]. It is therefore likely
that PDGF caused contraction of the floating FPCM via
its ability to stimulate fibroblast migration and hence
increase tractional forces.
IGF-1 did not significantly affect the contraction of
the FPCM at any of the concentrations tested. In vivo,
IGF-1 is normally found bound to one of 6 IGFBP,
predominantly IGFBP-3 [21]. Insulin-like growth factor
binding proteins have a role in modulating the binding
of IGF-1 to its receptor, and they can either strengthen
or inhibit the action of IGF-1 [22]. Therefore, delivery
of unbound IGF to cells, as was the case here, is likely to
have a different effect than if it was presented bound to
its binding proteins. Indeed, the addition of free IGF-1
to wounds has been shown to have adverse side effects,
including electrolyte imbalance and edema [21]. Lee et
al. [17] showed that although IGF-1 on its own at 30
or 100 ng/mL stimulated contraction of FPCM contain-
ing human foreskin fibroblasts (6.8% and 7.7% decrease
in diameter of gels within 6 h), just 1 ng/mL of IGF-
1 combined with 1 ng/mL IGFBP1 led to a decrease
in the matrix diameter by 14% within 6 h. Insulin-like
growth factor-1 has been shown to stimulate contraction
of FPCM containing human heart fibroblasts without
IGFBP [23]. Assouline et al. [19] showed that 10 ng/mL
IGF-1 in combination with 10 or 100 ng/mL epidermal
growth factor (EGF) stimulated contraction of collagen
gels containing human keratocytes, though if IGF was
combined with either PDGF or fibroblast growth factor,
contraction was inhibited. These papers therefore sug-
gest IGF-1 can stimulate contraction but that its effect
is dependent on other growth factors and its binding
protein.
Transforming growth factor 1 had no significant
effect on the contraction of the FPCM (Fig. 3), despite the
fact that it is commonly acknowledged as a key growth
factor in the wound contraction process owing to its
ability to stimulate myofibroblast differentiation [24].
However, the floating matrices used here do not cause
fibroblasts to differentiate because of the low tension
within the collagen matrix, and instead, tractional force
resulting from fibroblast migration is thought to be the
main mechanism stimulating contraction [14]. Ander-
sen et al. [16] and Ellis and Schor [25] demonstrated
that TGF1 inhibited migration of human keratocytes
and dermal fibroblasts, respectively. It is therefore likely
that although TGF1 did not inhibit fibroblast migration
in the present experiment, (as this would have led to a
lower contraction of the gels compared to the control), it
did not stimulate contraction either. The concentrations
used here have previously been shown to stimulate con-
traction of FPCM in other species [15,26], and effects on
equine cell proliferation have also been shown at these
concentrations [27,28]. In the present experiment, results
were replicated using multiple batches of TGF1 (results
not shown), indicating this result was not owing to a
denatured batch of TGF1.
It has been shown that the equine TGF1 amino acid
sequence is unique to the horse, with a difference of
two amino acids in comparison to some other mam-
malian species [29]. Although Nixon et al. [29] claim
that these amino acid substitutes in the horse are unlikely
to lead to major functional differences, if these substitu-
tions occur in the region of the protein that binds to the
TGF receptors, then the human TGF1 used in these
experiments could have had a reduced binding affinity
with equine TGF receptors, thus leading to the lack of
action reported here. A basic local alignment search tool
(BLAST) search shows that the structures of TGFRI
and TGFRII are, respectively, 98% and 100% homol-
ogous between the human and equine proteins. If the
unique structure of equine TGF1 altered its ability to
bind to its receptors, then it would be expected that a cor-
responding structural change would also be observed in
the receptor. Therefore, the close homology between the
receptors of the two species suggests that equine TGF
receptors should recognize human TGF1, although the
affinity may still be reduced.
Others have also published papers using TGF1 from
other species on equine cells [27,28], which also supports
the notion that human TGF1 will react with equine
TGF receptors. It has also been shown that TGF1
does not stimulate contraction in oral mucosal fibroblasts
compared to dermal fibroblasts [30], thus the fact that
TGF1 did not stimulate cells to contract FPCM here
may be linked to the use of oral fibroblasts within this
experiment. Therefore, the results gained in our study
can probably be explained through a combination of the
model used and the phenotype of the cells embedded
within it.
For each cell signaling pathway investigated, two
inhibitors were used, as recommended by Davies et al.
[18]. Although the inhibitors chosen here had been well
characterized for their specificity, no inhibitor will exclu-
sively inhibit only one protein kinase, but instead they
inhibit a range of kinases with varying degrees of speci-
ficity [18]. Therefore, if two different inhibitors with
different spectra of specificity are used, and both of
these inhibitors produce identical results, it gives confi-
dence that the intended pathway being studied is actually
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the primary one being inhibited [18]. Both Rho-kinase
inhibitors Y-27632 and hydroxyfasudil reduced the con-
traction of PDGF-stimulated FPCM to levels observed in
the controls (Fig. 4), suggesting that Rho-kinase plays a
vital role in mediating the effect of PDGF. This is the first
time that the effect of Rho-kinase inhibitors on equine
cells has been investigated. Nevertheless, these results
are in agreement with those for PDGF-stimulated FPCM
treated with Rho-kinase inhibitors in other species [7,8].
Rho-kinase is an essential enzyme in the formation
and contraction of actin stress fibers that are important
in the generation of tractional force [31]. In addition to
stress fibers, Rho-kinase activity is intimately linked to
the expression of focal adhesions, and inactivation of
Rho-kinase leads to rapid loss of integrin clusters on the
cell surface [32]. Crucially, however, when fibroblasts
are embedded into floating collagen gels, the low tension
leads to an automatic loss of stress fibers and focal adhe-
sions [33], which is probably a result of natural inhibition
of Rho-kinase activity owing to decreased cytoskeletal
tension [34]. This finding suggests that inhibiting Rho-
kinase does not disrupt stress fiber formation in floating
gels because there are none to disrupt, but that instead
Rho-kinase must have an alternative effect.
Grinnell [35] suggests that the requirement for Rho-
kinase in floating matrices might be a reflection of the
requirement of the cell to maintain cytoskeletal integrity.
Rho-kinase has been implicated in regulation of micro-
tubule dynamics [36]. Contraction of floating FPCM
containing a low to moderate cell density, as was the
case in the experiments in this study, is dependent on
microtubules [37]. Inhibitor Y-27632 has been shown
to alter the organization of microtubules in mice [38],
and this change in morphology may be enough to alter
the ability of the cell to transmit force to the matrix.
More research investigating the effect of Rho-kinase
inhibitors on microtubule dynamics in equine fibroblasts
embedded in floating FPCM is needed to elucidate the
mechanism of inhibition.
Inhibitors SB203580 and SB202190 also blocked the
contraction of PDGF-stimulated FPCM back to con-
trol levels (Fig. 5), suggesting that p38 also plays a
vital role in mediating PDGF-stimulated contraction.
Platelet-derived growth factor is a strong stimulator
of mitogen-activated protein kinase (MAPK) pathways,
including p38 [7]. This is the first time that inhibition
of p38 has been studied using equine cells. Both Hirano
et al. [9] and Li et al. [7] reported significant inhibition
of contraction of FPCM by SB203580 and SB202190
on rat fibroblasts and bovine aortic smooth muscle cells,
respectively. However, in both papers, the contraction
was not reduced to the levels seen in the control FPCM.
This finding is possibly a result of differences in the
treatments, model, and/or species; Hirano et al. [9] used
2.5% FBS or thrombin and FPCM that had been attached
for 3 d, and Li et al. [7] used 10% FBS and a cell con-
centration over 10 times higher than that used here. It
can therefore be concluded that stimulation of p38 by
PDGF is an important signaling cascade responsible for
the generation of tractional forces in FPCM.
5. Conclusions
The results presented here show that in floating
FPCM containing equine oral fibroblasts, PDGF is a
potent stimulator of contraction, whereas neither IGF-
1 nor TGF1 stimulated contraction in this model.
Platelet-derived growth factor appears to stimulate this
contraction via both the Rho-kinase and p38 signaling
pathways. This experiment has established some of the
growth factors and signaling pathways that potentially
control the initiation of wound contraction via tractional
force in a model containing oral fibroblasts, which thus
represents a wound that would heal scarlessly. We intend
to continue this research using fibroblasts obtained from
the limbs of horses, because of the poor healing nor-
mally seen on the legs of horses relative to the buccal
cavity. Differences between the two models could pro-
vide insight into why limb wounds heal so poorly, and
whether manipulation of both the growth factor profile
and the Rho-kinase and p38 signaling pathways may
provide a method of promoting wound contraction in
vivo.
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